Sickle Cell Anemia

Sickle Cell Anemia (SCA), known internationally as Sickle Cell Disease (SCD), is a hereditary blood disorder characterized by the production of abnormal hemoglobin S (HbS) due to a mutation in the hemoglobin gene. This structural defect causes red blood cells to lose their normal round and flexible shape and assume a sickle form. Sickled erythrocytes lose their elasticity, adhere to vessel walls, and cause microvascular occlusions, leading to inadequate oxygen delivery to tissues. Over time, hypoxia results in severe clinical complications. SCA is one of the most common hemoglobinopathies worldwide and is inherited in an autosomal recessive pattern. The disease shows high prevalence in populations of African origin, as well as in communities from the Mediterranean region, the Middle East, and South Asia.

Pathophysiology

Sickle cell anemia is a hereditary hemoglobinopathy caused by a single nucleotide substitution (GAG → GTG) in the sixth codon of the β-globin gene, resulting in the replacement of glutamic acid with valine. This point mutation leads to the synthesis of HbS instead of normal hemoglobin A (HbA). While HbS remains stable under normal oxygen conditions, it polymerizes under triggering factors such as low oxygen tension, acidosis, or dehydration, causing erythrocytes to adopt their characteristic sickle shape. This morphological change results in loss of erythrocyte flexibility, adhesion to endothelial surfaces, and formation of occlusive plugs in the microcirculation. Consequently, complications such as ischemia, painful vaso-occlusive crises, and organ damage occur. Additionally, these abnormal erythrocytes are rapidly destroyed by mechanical stress and the reticuloendothelial system, leading to chronic hemolytic anemia in affected individuals. The normal lifespan of erythrocytes, approximately 120 days, is reduced to an average of 10–20 days in sickle cell anemia. Continuous hemolysis releases free hemoglobin into circulation, which consumes nitric oxide (NO), contributing to endothelial dysfunction and pulmonary hypertension. All these processes form a complex pathophysiological picture that extends beyond mere erythrocyte morphology, involving chronic inflammation, immune system dysregulation, and progressive multiorgan involvement.

Clinical Manifestations

Sickle cell anemia is a chronic multisystem disorder with a broad spectrum of clinical manifestations. Symptoms commonly associated with anemia include fatigue, easy tiring, and pallor. Vaso-occlusive crises are among the most characteristic features of the disease and often present as severe complications such as hand-foot syndrome, acute abdominal pain, acute chest syndrome, and stroke. Additionally, sequestration crises involving splenic and hepatic blood pooling, aplastic crises due to bone marrow suppression, and hyperhemolytic crises characterized by increased hemolysis represent significant complications that worsen the clinical course. Chronic organ damage may develop over time, including jaundice, hepatosplenomegaly, bone deformities, cardiomyopathy, renal dysfunction, and growth and developmental delays. Furthermore, the physical limitations and persistent health issues associated with the disease can lead to serious psychosocial problems such as social isolation, depression, anxiety, and low self-esteem.

Importance of Infections

Infections are among the most significant complications of Sickle Cell Anemia (SCA), severely impacting quality of life and leading to high morbidity and mortality. Particularly due to functional asplenia (loss of splenic function), the immune system becomes compromised. This immunodeficiency is linked to mechanisms such as complement system dysfunction, reduced phagocytic function, and impaired opsonization. The most common and life-threatening infections include Streptococcus pneumoniae, Haemophilus influenzae type B, and Salmonella species. Therefore, prevention, rapid diagnosis, and effective treatment of infections are paramount in disease management. Prophylactic antibiotic use, vaccination programs, and early intervention are fundamental strategies for reducing infection-related complications in these patients.

_{Sickle Cell Anemia} (iStock)

Diagnostic Methods

The diagnosis of sickle cell anemia can be established shortly after birth through newborn screening programs. In neonatal screening tests, the presence of HbS can be detected using methods such as “hemoglobin electrophoresis” or “high-performance liquid chromatography (HPLC).” Once diagnosed, molecular genetic testing can identify the specific mutation in the β-globin gene. Family history, ethnic background, and clinical findings also contribute to the diagnostic process. Regular follow-up tests are essential for diagnosed individuals, including complete blood count, reticulocyte count, bilirubin levels, and hemolytic parameters. In patients with complications, advanced imaging techniques such as transcranial Doppler ultrasonography may be used to assess stroke risk. The diagnostic process not only identifies the disease but also forms the basis for individualized treatment planning.

Treatment Approaches

Due to its chronic and genetic nature with systemic effects, sickle cell anemia necessitates a multidisciplinary treatment approach. Treatment strategies focus on preventing complications, alleviating symptoms, and improving quality of life.

Prevention and Management of Infections

In individuals with sickle cell disease, defense mechanisms against infections are impaired, particularly due to functional asplenia. Consequently, infections are among the most common and deadliest complications. Fever is considered a potential sign of bacterial infection and must be promptly treated with broad-spectrum intravenous antibiotics without delay. Daily penicillin prophylaxis initiated at birth is highly effective in reducing infection risk. In addition to prophylactic antibiotic therapy, comprehensive vaccination programs including conjugated pneumococcal (PCV13), polysaccharide pneumococcal (PPSV23), Haemophilus influenzae type B (Hib), Neisseria meningitidis, and influenza vaccines must be strictly implemented. Patients with high fever, deteriorating clinical condition, or those in high-risk groups should be closely monitored in the hospital for possible sepsis.

Transfusion Therapy

Red blood cell transfusions play a critical role in managing acute complications and preventing chronic disease progression. Depending on the clinical condition, simple red blood cell transfusion or exchange transfusion (erythrocytapheresis) may be performed. Simple transfusions are preferred when hemoglobin levels fall below 7 g/dL, while exchange transfusions are used in conditions such as acute chest syndrome or stroke to achieve more effective outcomes. Post-treatment hemoglobin levels should not exceed 10 g/dL, as higher levels may increase blood viscosity and lead to new complications. Donor selection must be carefully performed with attention to antigen compatibility to enhance transfusion safety. This approach is crucial in reducing the risk of alloimmunization and transfusion reactions.

Crisis Management

Vaso-occlusive crises are the most frequent and severely quality-of-life-impacting complications of sickle cell anemia. Effective crisis management is vital in life-threatening situations such as acute chest syndrome, stroke, and severe pain episodes. Acute chest syndrome presents as a serious clinical condition with chest pain, respiratory distress, and pulmonary infiltrates on imaging. In such cases, hospitalization is required with multidisciplinary management including intravenous fluid therapy, oxygen support, antibiotic administration, and, if necessary, red blood cell transfusion. Management of painful crises is based on eliminating triggering factors, ensuring adequate hydration, and effective pain control. Mild crises can be managed at home with supportive care, while severe cases require hospitalization with intravenous fluids and opioid analgesia.

Pharmacological Treatment

One of the most important medications in the medical management of sickle cell anemia is hydroxyurea. This agent increases fetal hemoglobin (HbF) production, thereby inhibiting erythrocyte sickling and significantly reducing the frequency of vaso-occlusive crises and hospital admissions. Hydroxyurea is a well-established and safe long-term treatment option. In patients receiving frequent transfusions, iron overload can accumulate over time and cause damage to the liver, heart, and other organs; therefore, iron chelation therapy is mandatory. Agents such as deferoxamine and deferasirox are commonly used for iron chelation. In recent years, novel drugs such as L-glutamine, voxelotor, and crizanlizumab have also been introduced as treatment options for specific indications. Alongside these medical approaches, allogeneic hematopoietic stem cell transplantation remains the only curative treatment currently available for sickle cell anemia. When a suitable donor is found, this procedure can potentially eliminate the disease permanently. However, due to procedure-related complications and immunological risks, it is reserved for specific patient groups.

Management Before Surgical Interventions

Special precautions are mandatory before any surgical procedure in individuals with sickle cell anemia. Physiological conditions that can trigger sickling, such as hypoxia, hypothermia, and dehydration, must be strictly avoided. Preoperatively, the patient’s hemoglobin level should be raised above 10 g/dL, and the HbS percentage should be reduced below 30%. This goal can be achieved through simple transfusion or, if necessary, exchange transfusion. Surgical interventions performed without adequate preparation can lead to life-threatening complications; therefore, this process must be managed with meticulous care.

Preventive Health and Genetic Counseling

Long-term control of the disease is not limited to clinical treatments alone. Widespread implementation of preventive health services and community-based awareness initiatives is essential for effective disease management. Structured educational programs for families and patients provide significant benefits in crisis management, medication adherence, and infection prevention. Genetic counseling services aim to identify carrier status and prevent transmission of the disease to future generations. Furthermore, advanced technologies such as prenatal diagnosis and preimplantation genetic diagnosis serve as powerful tools for disease prevention. Thanks to newborn screening programs, early diagnosis is possible, enabling timely initiation of appropriate treatment and reducing morbidity and mortality rates.

Sickle cell anemia is a chronic disease requiring lifelong follow-up and a multidisciplinary approach. Preventing infections, managing crises, and reducing complications improve patients’ quality of life. Genetic counseling and early diagnosis play a crucial role in reducing disease prevalence and the incidence of severe clinical manifestations.